Brief: Simcere Pharmaceutical Announces Approval For Marketing Of Yingmule In China By NMPA
03/09/2026 16:51
BRIEF-Simcere Pharmaceutical Announces Approval For Marketing Of Yingmule In China By NMPA Sept 3 (Reuters) - Simcere Pharmaceutical Group Ltd 2096.HK:
APPROVAL FOR MARKETING OF YINGMULE IN CHINA BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Further company coverage: 2096.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Simcere Pharmaceutical
See all newsBrief: Simcere Pharmaceutical Announces Approval For Marketing Of Yingmule In China By NMPA
Simcere Pharmaceutical jumps most in two months on Roche tie-up
Roche signs global licensing pact for Simcere's experimental blood cancer drug (updated)
Roche signs global licensing pact for Simcere's B-cell cancer drug candidate
Brief: Simcere Pharmaceutical Enters Exclusive Global Licensing Agreement With Roche For SIM0660